borderline significantp = 0.05
Thirty-day all-cause mortality showed a borderline significant difference favoring TAVR (RR 0.55; 95 % CI 0.30–1.01; p = 0.05).
Thirty-day all-cause mortality showed a borderline significant difference favoring TAVR (RR 0.55; 95 % CI 0.30–1.01; p = 0.05).
Although results show a favorable trend for TAVR in younger patients and those with low surgical risk, caution is warranted for patients with bicuspid aortic valves due to potential increased risks.